- Regulatory
changes and shifting attitudes are contributing to the rapid growth of the
legal cannabis sector
- According
to a CIBC World Markets report, the industry has many representatives but
only a few possess what it takes to dominate the new global market
- Management
team strength, brand development, capital allocation, price target and
distribution channel information can tell investors who the frontrunners
in the industry are
- Based
on these factors, The Green Organic Dutchman Holdings is shaping up as a
leading entity to watch in 2019 and the years to come
As cannabis is rising to prominence, investors are turning
their eyes to industry opportunities that have the best long-term potential.
Currently, dozens of small and medium-sized businesses are generating moderate
revenues, but only a few have what it takes to dominate the new global market,
an Institutional Equity Research report by CIBC World Markets suggests.
The report pinpoints numerous factors that will influence
the growth and development of industry representatives as cannabis continues
gaining steam. These primary factors include a strong management team,
strategy, capital allocation, brand development, distribution channels, price
target and production and supply chain, among many others.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX:
TGODF), a cannabis-focused research and development company, ticks the boxes.
For a start, the company has been working hard to strengthen its managerial
team. On January 8, 2019, TGOD announced the addition of deep pharmaceutical
and medical experience to the board of directors via the appointment of Dr.
Caroline MacCallum and Jacques Dessureault (
http://ibn.fm/sOYJk).
MacCallum is a leading cannabinoid-based medicine expert who
has published the results of numerous academic trials pertaining to the dosage,
use and administration of medical cannabis. Dessureault is known for his
extensive pharmaceutical career, including an international role with Novartis.
Also in January, the company appointed Dr. Rav Kumar as its
chief science officer (
http://ibn.fm/OcMNO).
Kumar has over 25 years of experience in the pharmaceutical industry. His
international experience in Europe, North America and Asia focused on
discovery, formulation, development, quality and compliance. In 2017, Kumar
received the Canadian Pharmaceutical Sciences award for leadership.
According to the CIBC World Markets report, strong
management teams offer investors the best guidelines in terms of entities that
have the potential to become global leaders.
The management’s vision for the future is much more
important in this industry than a valuation, the report concludes. While a valuation
is still relevant, it matters less than in other industries. It has had little
effect on cannabis trading patterns, while regulatory change, external
investment and demonstration of operational execution have established
themselves as much more important factors.
The industry report also examines potential stock catalysts
that are bound to impact the sector even further in the years to come.
Strengthening the Tenth Amendment through the Entrusting
States Act (STATES Act) is expected to be the likeliest path to de facto
national legalization of cannabis in the United States. Deliberations are set
to begin in 2019, potentially contributing to approval in 2020. The aim of the
act is to legalize the possession, manufacturing and distribution of cannabis
wherever such activities have been authorized by state law. Thus, if usage is
permitted on a state level, it would also be granted on a federal level.
The Federal Farm Bill in the U.S. is yet another major step
forward. The Federal Farm Bill removed hemp from the list of controlled
substances, as long as the THC content remained below 0.3 percent. Complete
removal is anticipated, and steps toward this major regulatory shift are
expected in 2019 and throughout 2020.
A Global Shift
Progress isn’t just being made in North America. Several
important milestones have also been hit globally.
Countries across the globe are starting to redefine their
drug policies in an attempt to root out underground economies. A changing
public opinion toward the use of cannabis products is also impacting
decision-makers.
According to the industry report, countries like Germany,
Colombia, Argentina and England will possibly introduce major policy changes in
2019 to ensure adult-use legalization. The report creators believe that
Canadian companies who have already passed through a nationwide legislative
reform may have an advantage in such international settings.
A final driver for change is the constant influx of
information pertaining to the uses and the benefits of cannabis.
Multiple clinical trials are currently in the process of
execution, and they’ll begin generating data in the very near future.
Significant discoveries are anticipated, shaping up public opinions and fueling
regulatory change even further.
As bans are lifted and medical research is carried out,
discoveries will benefit cannabis producers. Until now, the medicinal benefits
of cannabis had been supported predominantly by anecdotal evidence – a fact
that’s rapidly changing.
The report concludes that the future of the industry is
bright, regardless of the fact that various challenges are yet to be overcome.
It is currently difficult to develop recognizable brands in Canada because of
Health Canada advertising and labeling restrictions. There are also product
limitations suggesting that companies are stuck within a limited scope of
possibilities.
More developed markets, however, do matter, and they do
provide chances for growth.
TGOD Eyeing International Markets
Canadian companies like The Green Organic Dutchman are
already pursuing international opportunities.
On January 25, 2019, TGOD announced a definitive agreement
for the launch of European production. The agreement with Queen Genetics/Knud
Jepsen A/S establishes joint ventures in Denmark with a goal of expanding
production into future low-cost European jurisdictions (
http://ibn.fm/3wiet).
In October 2018, a HemPoland acquisition was finalized,
further enabling the company to expand its international footprint. TGOD has
also invested in Jamaica, as well as in Mexico.
Via these strategic partnerships and acquisitions, TGOD is
expecting its annual capacity across Canada and Jamaica to reach 170,000
kilograms. The hemp capacity in Poland will contribute even further to the
company’s international advantage.
The Green Organic Dutchman is a premium organic cannabis
company focusing on the legal recreational and medicinal markets in Canada,
Latin America and Europe. Sustainable, all-natural principles are the heart of
the company’s corporate philosophy, with all TGOD products being
laboratory-tested to ensure quality.
Emerging Industry Leaders
The CIBC World Markets report lists three other cannabis
companies among the most likely to secure dominating positions on the global
market: Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), Cronos
Group Inc. (TSX.V: MJN) (OTC: PRMCF) and Aphria Inc. (TSX: APHA)
(NYSE: APHA). CIBC has initiated coverage of all three starting January 17.
The report notes that Canopy and Cronos are likely to become leaders in their
global fields, mostly due to their strong management, while Aphria, although a
manufacturing and automation expert, may face some problems related to capital
allocation and corporate governance, which could deter investors.
Canopy Growth, the first North American cannabis
company to be publicly traded, is a diversified hemp and cannabis organization
that offers a wide range of distinct brands and products. The company operates
in more than 15 countries across five continents and runs 10 licensed cannabis
production facilities with a production capacity of over 4.3 million square
feet, including 500,000 square feet of GMP certified production space. With a
declared goal of becoming the number one cannabis company in the world, Canopy
Growth is also dedicated to educating the public, as well as health care
practitioners, about the benefits of cannabis via robust clinical research,
product and process innovation and state-of-the-art market execution.
Cronos Group, a globally diversified and vertically
integrated cannabis company, operates across five continents via multiple
international production and distribution platforms. The company also runs two
wholly owned Canadian licensed producers under Health Canada’s Access to
Cannabis for Medical Purposes Regulations. Cronos Group’s goal is to create the
most valuable international cannabis community and set best practices in the
field by building industry-leading companies and an iconic international brand
portfolio while developing disruptive intellectual property.
Aphria, one of the earlier Canadian licensed
producers, has a strong commitment to innovation and product quality at a low
cost. The company works continuously to bring breakthrough innovation to the
global cannabis market and to set the standard for the low-cost production of
clean and safe pharmaceutical-grade cannabis. Aphria operates in more than 10
countries across five continents and is dedicated to meeting the needs of every
consumer segment while building sustainable shareholder value via its
diversified approach to global expansion, innovation and strategic
partnerships.
Alongside The Green Organic Dutchman, these companies are
likely to become dominant forces in the cannabis market, both nationally and
worldwide, due to their strong commitments to innovation, education and global
expansion. With powerful brand portfolios and an impressive international
reach, each of these companies could provide significant shareholder value for
the foreseeable future.
For more information, visit the company’s website at
www.TGOD.ca
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published:
http://www.missionir.com/disclaimer.html
